Bui K - Search Results

1

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation.

Lu G, Lin J, Bui K, Curnutte JT, Conley PB. Lu G, et al. Among authors: bui k. Res Pract Thromb Haemost. 2020 Aug 27;4(8):1282-1294. doi: 10.1002/rth2.12418. eCollection 2020 Nov. Res Pract Thromb Haemost. 2020. PMID: 33313467 Free PMC article.

2

Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation.

Floettmann E, Bui K, Sostek M, Payza K, Eldon M. Floettmann E, et al. Among authors: bui k. J Pharmacol Exp Ther. 2017 May;361(2):280-291. doi: 10.1124/jpet.116.239061. Epub 2017 Mar 23. J Pharmacol Exp Ther. 2017. PMID: 28336575 Free PMC article.

3

Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study.

Eldon MA, Kugler AR, Medve RA, Bui K, Butler K, Sostek M. Eldon MA, et al. Among authors: bui k. Clin Pharmacol Drug Dev. 2015 Nov;4(6):434-41. doi: 10.1002/cpdd.206. Epub 2015 Sep 4. Clin Pharmacol Drug Dev. 2015. PMID: 27137715 Clinical Trial.

4

Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol.

Eldon MA, Kugler AR, Medve RA, Bui K, Butler K, Sostek M. Eldon MA, et al. Among authors: bui k. Clin Pharmacol Drug Dev. 2015 Nov;4(6):442-8. doi: 10.1002/cpdd.204. Epub 2015 Sep 4. Clin Pharmacol Drug Dev. 2015. PMID: 27137716 Clinical Trial.

5

The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol.

Bui K, She F, Sostek M. Bui K, et al. J Clin Pharmacol. 2014 Dec;54(12):1375-82. doi: 10.1002/jcph.349. Epub 2014 Jul 1. J Clin Pharmacol. 2014. PMID: 24946021 Clinical Trial.

6

Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist.

Bui K, Zhou D, Xu H, Floettmann E, Al-Huniti N. Bui K, et al. Clin Pharmacokinet. 2017 Jun;56(6):573-582. doi: 10.1007/s40262-016-0479-z. Clin Pharmacokinet. 2017. PMID: 28035588 Review.

7

Preclinical pharmacology of AZD2327: a highly selective agonist of the δ-opioid receptor.

Hudzik TJ, Maciag C, Smith MA, Caccese R, Pietras MR, Bui KH, Coupal M, Adam L, Payza K, Griffin A, Smagin G, Song D, Swedberg MD, Brown W. Hudzik TJ, et al. Among authors: bui kh. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204. doi: 10.1124/jpet.111.179432. Epub 2011 Mar 28. J Pharmacol Exp Ther. 2011. PMID: 21444630

8

Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients.

Al-Huniti N, Chapel S, Xu H, Bui KH, Sostek M. Al-Huniti N, et al. Br J Clin Pharmacol. 2016 Jan;81(1):89-100. doi: 10.1111/bcp.12756. Epub 2015 Oct 27. Br J Clin Pharmacol. 2016. PMID: 26317320 Free PMC article.

9

Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid-Induced Constipation.

Al-Huniti N, Xu H, Zhou D, Aksenov S, Fox R, Bui KH. Al-Huniti N, et al. CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):705-711. doi: 10.1002/psp4.12229. Epub 2017 Sep 25. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28782266 Free PMC article. Clinical Trial.

10

An Open-Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects.

Bui K, Birmingham B, Diva U, Berger B. Bui K, et al. Clin Pharmacol Drug Dev. 2017 Jul;6(4):420-427. doi: 10.1002/cpdd.335. Epub 2017 Jan 27. Clin Pharmacol Drug Dev. 2017. PMID: 28127938 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

338 results

Search Page

Filters